Compare QUBT & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QUBT | LEXX |
|---|---|---|
| Founded | 2001 | 2004 |
| Country | United States | Canada |
| Employees | N/A | 7 |
| Industry | Computer Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 16.2M |
| IPO Year | 2019 | N/A |
| Metric | QUBT | LEXX |
|---|---|---|
| Price | $6.66 | $0.73 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | ★ $17.00 | $1.50 |
| AVG Volume (30 Days) | ★ 9.2M | 141.9K |
| Earning Date | 03-02-2026 | 04-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 84.93 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $682,000.00 | N/A |
| Revenue This Year | $3,210.56 | N/A |
| Revenue Next Year | $51.26 | $601.47 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 82.84 | N/A |
| 52 Week Low | $5.76 | $0.46 |
| 52 Week High | $25.84 | $1.75 |
| Indicator | QUBT | LEXX |
|---|---|---|
| Relative Strength Index (RSI) | 34.37 | 53.26 |
| Support Level | N/A | $0.62 |
| Resistance Level | $9.15 | $0.87 |
| Average True Range (ATR) | 0.40 | 0.07 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 2.23 | 52.48 |
Quantum Computing Inc is an integrated photonics and quantum optics technology company that provides accessible and affordable quantum machines to the world today. Its products are designed to operate at room temperature and low power at an affordable cost. The Company's portfolio of core technologies and products offer capabilities in the areas of high-performance computing, artificial intelligence, and cybersecurity, as well as remote sensing applications.
Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.